Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
63
resultados
Última actualización
09/10/2025 [12:35:00]
Resumen de: AU2023406508A1
The present disclosure provides methods of treating acute myeloid leukemia (AML) and methods of determining responsive to AML treatment regimes, the methods comprising identifying the presence or absence of monocytic leukemia stem cells (m-LSCs), including CD70+ m-LSCs, in a sample from a subject.
Resumen de: EP4628071A1
The invention discloses a targeted nanoscale particle, a targeted cell, a preparation method therefor, and use thereof. The targeted nanoscale particle is bound to the outer surface of the targeted cell, and is composed of a plurality of proteins interconnected via a first binding site. The targeted nanoscale particle further comprises a second binding site, and is bound to the outer surface of a target cell via the second binding site. In an exemplary embodiment, the targeted nanoscale particle can promote the interaction between the two types of cells by simultaneously binding to a chimeric antigen receptor T cell and a leukemia cell, thereby promoting the recognition and killing of the leukemia cell by the chimeric antigen receptor T cell. In addition, the internal cavities of the proteins in the targeted nanoscale particle provide space for loading of a chemotherapeutic drug, thus realizing the combination therapy of the chimeric antigen receptor T cell and other therapies while loading the drug.
Resumen de: WO2025203031A2
Methods of detecting cancer in a subject in need thereof, comprising ascertaining the methylation status of at least four methylation sites in the same double-stranded cell-free DNA (cfDNA) molecule and detecting the presence of at least two sites that are methylated and at least two sites that are unmethylated in the at least four methylation sites indicating that the subject suffers from cancer are provided. Methods of quantifying molecules of cfDNA and also provided, as are methods of detecting and quantifying plasma cell DNA. Methods of diagnosing multiple myeloma or predicting progression of smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma in a subject are also provided.
Resumen de: US2025302895A1
Methods of treatment and/or prevention of tumours, preferably of solid tumours, more preferably of breast cancer, melanoma, bladder cancer, head and neck cancer, Hodgkin's lymphoma, kidney cancer, non-small cell lung cancer using fermented supernatant, or fractions thereof, of the Lactobacillus casei or paracasei species are disclosed. The species is the strain deposited according to the Budapest Treaty with No. CNCM I-5220 and/or includes in its DNA genome a DNA sequence essentially identical to one of: SEQ ID No 1 to 5.
Resumen de: AU2025230686A1
The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other protective agents. 5 The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other 5 protective agents. ep h e p r e s e n t i n v e n t i o n p r o v i d e s a v a c c i n e f o r f e l i n e l e u k e m i a v i r u s a n d e p m e t h o d s o f m a k i n g a n d u s i n g t h e v a c c i n e a l o n e , o r i n c o m b i n a t i o n s w i t h o t h e r p r o t e c t i v e a g e n t s
Resumen de: US2025302939A1
Provided herein is a nucleic acid-based vaccine for human T-cell leukemia virus type 1 (HTLV-1). In some aspects, the vaccine includes a combination of nucleic acid molecules encoding HTLV-1 gag protein and one or both of Type A HTLV-1 Envelope (Env) and Type C HTLV-1 Env. In some aspects, the vaccine includes a combination of nucleic acid molecules encoding HIV-1 gag protein and one or both of Type A HTLV-1 Envelope (Env) and Type C HTLV-1 Env. When administered to a subject, the Env and Gag proteins are expressed in the host and form HTLV-1 virus-like particles (VLPs) that are secreted from cells within the host and elicit an immune response that inhibits HTLV-1 infection.
Resumen de: AU2025230668A1
Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma. Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma. ep i s c l o s e d a r e m e t h o d s o f t r e a t i n g a s u b j e c t h a v i n g h i g h - r i s k m u l t i p l e m y e l o m a , e p m e t h o d s o f a c h i e v i n g n e g a t i v e m i n i m a l r e s i d u a l d i s e a s e s t a t u s i n a s u b j e c t h a v i n g m u l t i p l e m y e l o m a , a n d m e t h o d s o f p r e d i c t i n g a l i k e l i h o o d o f , o r d e c r e a s i n g a r i s k o f , r e l a p s e a n d o r d i s e a s e p r o g r e s s i o n i n a s u b j e c t h a v i n g m u l t i p l e m y e l o m a
Resumen de: US2025305071A1
A method for detecting conjunctival diseases such as conjunctival MALT lymphoma, and an aging biomarker that serves as an indicator of the aging state of a subject are provided. The method for detecting conjunctival diseases comprises a step of comparing a microbial community structure of a microbiota in an ocular surface tissue specimen sampled from a healthy person with a microbial community structure of a microbiota in an ocular surface tissue specimen sampled from a subject to determine that the ocular surface tissue specimen of the subject has an indication of the conjunctival diseases. The aging biomarker comprises bacterial species which belongs to the Corynebacteriaceae family or the Propionibacteriales family in an ocular surface tissue.
Resumen de: WO2025202213A1
The present invention relates to lipid nanoparticle loaded with antitumoral agent and functionalized to target immunosuppressive cells. Inventors developpe valrubicin-loaded immunoliposomes (Val-ILs). A small amount of valrubicin incorporated into Val-ILs induces leukemia cell death in vivo, suggesting that Val-ILs could be used to treat acute leukemia cells. Inventors also demonstrated that Val-ILs could reduce the risk of contamination of CD34+ hematopoietic stem cells by acute leukemia cells during autologous peripheral blood stem cell transplantation. They also highlighted the potential of Val-ILs to target immunosuppressive cell populations in the spleen. The most efficient Val-ILs were found to be those loaded with CD11b,CD223, CD64, TIM1, CD200R3, CD204, CD49b, VEGFR2 and SIGLECF antibodies. This study provides the effectiveness and ease of preparation of Val-ILs as a novel nanoparticle technology. In the context of cancers, Val-ILs have the potential to be used as a precise and effective therapy based on targeted vesicle-mediated cell death.
Resumen de: WO2025202279A1
Monitoring active disease or progressive disease under therapy in chronic lymphocytic leukemia (CLL) represents a challenge to earlier and better adapt therapeutic strategy, notably in the era of targeted therapies in which minimal residual detection or mutations are sometimes not associated to poor clinical outcome. By following CLL patients before treatment (Binet stages A and B/C) or during targeted therapy, the Inventors developed a new flow cytometric method, based on CD69, CD49d, CD20 and CD279 expression at the surface of CD19+/CD5+ B leukemic cells. Analyses of these markers alone or in combination show that CD69/CD49d/CD20/CD279 co-expression (quadruple population, QP) > 0.5% is the best criterion predicting CLL active disease or progression under therapy. This new flow cytometry immunophenotyping could help clinicians to monitor CLL evolution and quickly adapt their therapeutic strategy. Accordingly, the present invention relates to an ex vivo method for predicting active Chronic Lymphocytic Leukemia (CLL) or progressive CLL under therapy in a subject suffering from CLL, comprising the step of quantifying a population of CD69+/CD49d+/CD20+/CD279+ cells in a sample obtained from the subject.
Resumen de: WO2025207791A1
Aspects are directed to a novel small molecule inhibitor of Nsp16 having a chemical formula of (N-9-(2R,3R,4S,5S)-5-(chloromethyl)-3,4-dihydroxy-tetrahydrofuran-2-ylpurin-6-ylprop-2-enamide) (AT501) or analogs thereof. Other aspects are directed to a therapeutic composition comprising AT501 or analogs thereof, further including antiviral compounds or anticancer compounds. Certain aspects are directed to a method of treating Coronavirus infection by administering AT501 or a composition thereof to a subject having or at risk of obtaining a Coronavirus infection caused by SARS-CoV-1 or SARS-CoV-2 virus. Certain aspects are directed to methods of treating cancer by administering AT501 or a composition thereof to a subject having or at risk of developing cancer, such as leukemia.
Resumen de: WO2025201464A1
Abametapir or a pharmaceutically acceptable salt thereof has antitumor activity and significant antitumor effects on gynecological tumors, digestive tract tumors, lung tumors, lymphomas, and the like. Abametapir has a significant inhibitory effect on the growth and development of various human tumor cells and tumors in tumor-bearing mice, and especially has a good inhibitory effect on triple-negative breast cancer. Abametapir or the pharmaceutically acceptable salt thereof has an effective antitumor effect by means of oral administration.
Resumen de: WO2025199993A1
The present invention belongs to the technical field of cancer immunotherapy, and particularly relates to a cholesterol-modified cationic liposome tumor vaccine, a preparation method therefor, and use thereof. In order to solve the problems of poor targeting and strong side effects of TLR agonists in anti-tumor treatment, the present invention provides a cationic liposome prepared from a cholesterol-modified 1V209 molecule, a cationic lipid component, cholesterol, and DSPE-PEG2000, and then the cationic liposome and ovalbumin 5 form the tumor vaccine by electrostatic adsorption. Animal experiments show that the vaccine can induce antigen-specific CD8+ T cells, activate lymphocytes, and generate stronger antigen cross-presentation, more memory T cells, antibodies, and cytokines. Prophylactic inoculation with the vaccine can significantly delay the progression of mouse melanoma and lymphoma and prolong the survival of mice. The combination use of the vaccine and a PD-1 checkpoint inhibitor can further enhance the anti-tumor effect. Therefore, the vaccine is a promising cancer vaccine.
Resumen de: WO2025208087A1
Disclosed herein, in certain embodiments, are systems and methods of detecting the presence of a skin condition using a machine learning model based on molecular risk factors. In some instances, the skin condition is cancer, such as cutaneous T cell lymphoma (CTCL). In some cases, the skin cancer can be mycosis fungoides (MF) or Sézary syndrome (SS).
Resumen de: US2025302842A1
Heterocyclic compounds, their stereoisomers and their pharmaceutically acceptable salts are useful in the treatment of many types of cancers, such as cancers of the breast, prostate, pancreatic, gastric, lung, colon, rectum, esophagus cancer, duodenum, tongue, pharynx, liver, kidney, bile duct, uterine body, cervix, ovaries, urinary bladder, and skin. Other cancers to be treated include brain tumor, neurinoma, clear cell carcinoma, non-small cell lung cancer, small cell lung cancer, hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer, bone tumor, vascular fibroma, glioblastoma, Neuroblastoma, sarcoma, neuroendocrine tumors, retinoblastoma, penile cancer, pediatric solid cancer, renal cell carcinoma, lymphoma, myeloma, leukemia, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, cutaneous T-cell lymphoma (CTCL), multiple myeloma (MM), myeloproliferative neoplasms (MPN), Myelodysplastic syndrome (MDS), polycythemia vera (PV), essential thrombocythemia, essential thrombocytosis (ET), and myelofibrosis (MF), and also including their metastases.
Resumen de: US2025302827A1
In certain embodiments, this disclosure relates to method of treating and diagnosing cancer by administering a Bcl-2 inhibitor optionally in combination with a mitochondrial complex II inhibitor. In certain embodiments, a subject is diagnosed with, exhibiting symptoms of, or at risk of cancer wherein the cancer is a hematological malignancy such as multiple myeloma, leukemia, or lymphoma.
Resumen de: WO2025202900A1
This invention relates to therapies for treating mantle cell lymphoma comprising a cyclin dependent kinase 4 (CDK4) inhibitor or a pharmaceutically acceptable salt thereof, and associated methods of treatment, pharmaceutical compositions, and uses thereof.
Resumen de: US2025304697A1
Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. CD1a is exclusively expressed in cortical T-ALLs, a major subset of T-ALL. The expression of CD1a is restricted to cortical thymocytes and neither CD34+ progenitors nor T-cells express CD1a during ontogeny, confining the risk of on-target/off-tumor toxicity. The present invention provides CD1a-targeting moieties comprising a CD1a-which may be placed into T cells. The resultant CARTs are suitable for the treatment of cortical T-ALLs.
Resumen de: US2025304689A1
The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).
Resumen de: US2025304705A1
The present disclosure relates to an orthogonal system comprising a first bi-specific polypeptide that comprises D-streptavidin or a variant thereof covalently linked to an antibody or antibody fragment and a second bi-specific polypeptide that comprises L-biotin covalently linked to a therapeutic or diagnostic agent. The disclosed systems can be useful in, for example, treating a disease or a condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Also described are peptides and polypeptides useful in preparing the disclosed bi-specific polypeptides and methods of making same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: US2025304589A1
The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
Resumen de: US2025302950A1
Disclosed herein are methods for treating classic Hodgkin lymphoma (cHL) in a subject in need thereof, comprising administering an IL-2 conjugate in combination with an anti-PD-1 antibody or antigen-binding fragment thereof.
Resumen de: US2025306026A1
This disclosure relates to the surprising and unexpected finding that the well-known cancer protein, Myeloid Cell Leukemia-1 (MCL-1), binds to and modulates the enzymatic activity of Very Long Chain Acyl CoA Dehydrogenase (VLCAD), thereby regulating fatty acid β-oxidation. This finding is employed in compositions and methods of treating cancer, metabolic diseases, or other conditions characterized by excessive fatty acid β-oxidation by blocking or reducing the energy production of cells (e.g., cancer) through inhibiting the MCL-1/VLCAD interaction and/or directly inhibiting VLCAD enzymatic activity. In addition, the disclosure features methods for identifying such agents that inhibit the interaction between MCL-1 and VLCAD or that inhibit VLCAD enzymatic activity.
Resumen de: MX2024014736A
The present invention relates to the treatment of elderly subjects (e.g., subjects aged 65 years or older) having relapsed and/or refractory (R/R) non-Hodgkin's lymphoma (NHL). More specifically, the invention pertains to the treatment of subjects having an R/R NHL by intravenous administration of mosunetuzumab.
Nº publicación: MX2025007460A 01/10/2025
Solicitante:
GERON CORP [US]
GERON CORPORATION
Resumen de: MX2025007460A
Methods of monitoring therapeutic efficacy in a subject with myelodysplastic syndrome (MDS) are provided. Also provided is a method of identifying a subject with MDS for treatment with a telomerase inhibitor, and methods of treating MDS. The methods include administering to the subject a telomerase inhibitor and assessing variant allele frequency (VAF) for one or more of the following genes: SF3B1, TET2, DNMT3A, ASXL1, and CUX1 in a biological sample obtained from the subject after administration of the telomerase inhibitor. In some cases, a 25% or more reduction in VAF identifies a subject who has an increased likelihood of benefiting from treatment with a telomerase inhibitor. In some instances, the telomerase inhibitor is imetelstat or imetelstat sodium.
BOPI
Sede Electrónica
